Articles by Maki Komiyama

What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?

Maki Komiyama, Moritake Iguchi, Hiromichi Wada, et al

Published:

Citation: European Cardiology Review 2024;19:e10.

DOI:

https://doi.org/10.15420/ecr.2023.50
Randomised Double-blind Placebo-Controlled Multicentre Trial for the Effects of Yokukansan in Smokers with Depressive Tendencies

Maki Komiyama, Yuka Ozaki, Hiromichi Wada, et al

Published:

Citation: European Cardiology Review 2023;18:e30.

DOI:

https://doi.org/10.15420/ecr.2023.18.PO13
Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients

Maki Komiyama, Gheorghe-Andrei Dan, Koji Hasegawa, et al

Published:

Citation: European Cardiology Review 2023;18:e14.

DOI:

https://doi.org/10.15420/ecr.2022.66
European Society of Cardiology Highlights: Late-breaking Trials – COVID-19

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2022;17:e04.

DOI:

https://doi.org/10.15420/ecr.2022.03
Coronavirus Disease 2019: Psychological Stress and Cardiovascular Diseases

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2021;16:e33.

DOI:

https://doi.org/10.15420/ecr.2021.10
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?

Maki Komiyama, Koji Hasegawa, Akira Matsumori, et al

Published:

Citation: European Cardiology Review 2020;15:e49.

DOI:

https://doi.org/10.15420/ecr.2020.17
Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019’

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e55.

DOI:

https://doi.org/10.15420/ecr.2020.25
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e58.

DOI:

https://doi.org/10.15420/ecr.2020.24
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e16.

DOI:

https://doi.org/10.15420/ecr.2020.11
Obesity and Cardiovascular Risk After Quitting Smoking: The Latest Evidence

Koji Hasegawa, Maki Komiyama, Yuko Takahashi, et al

Published:

Citation: European Cardiology Review 2019;14(1):60–1

DOI:

https://doi.org/10.15420/ecr.2019.4.2
ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

Maki Komiyama, Koji Hasegawa,

Citation: European Cardiology Review 2018;13(1):21–2.

DOI:

https://doi.org/10.15420/ecr.13.1.1.GE1
Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama, Hiromichi Wada, Hajime Yamakage, et al

Citation: European Cardiology Review 2017;12(2):96.

DOI:

https://doi.org/10.15420/ecr.2017:23:5
Analysis of Factors Associated with Smoking Relapse

Sayaka Shimada, Maki Komiyama, Hiromichi Wada, et al

Citation: European Cardiology Review 2017;12(2):111.

DOI:

https://doi.org/10.15420/ecr.2017:23:20